pharmaceutical investing Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1 Combination Trial
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
Triumph Gold's Executive Chairman Discusses Utah Silver-Gold Acquisition and Exploration Strategy in New INN CEO Insights Interview